コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 greater solution stability than alpha-methyl-5-hydroxytryptamine.
3 fibroblast growth factor receptor 1 (FGFR1)-5-hydroxytryptamine 1A (5-HT1A) receptor complexes have
4 e altered through serotonergic modulation of 5-hydroxytryptamine 1A (5-HT1A) receptors, which hyperpo
6 ve agonist radioligand for the serotonin 1A (5-hydroxytryptamine 1A [5-HT1A]) receptor in recombinant
7 across arousal states are affected when the 5-hydroxytryptamine 1A receptor (5-HT1A) agonist (R)-(+)
8 ctivation of G(i), by comparing Smo with the 5-hydroxytryptamine(1A) (5-HT(1A)) receptor, a quintesse
10 e measurement of activation of the serotonin 5-hydroxytryptamine-1A (5-HT(1A)) receptor expressed in
12 l evidence implicates the serotonin receptor 5-hydroxytryptamine 1B (5-HT1B) in the effects of cocain
14 sly that GSK3beta selectively interacts with 5-hydroxytryptamine-1B receptors (5-HT1BR) that have imp
16 mbled as a GPCR heteromer with the serotonin 5-hydroxytryptamine 2A (5-HT(2A)) receptor in the mouse
24 ribosomal S6 kinase 2 (RSK2) interacts with 5-hydroxytryptamine(2A) (5-HT(2A)) serotonin receptors a
27 ies suggest that cis-UCA binds to serotonin (5-hydroxytryptamine) 2A (5-HT(2A)) receptor and that ant
28 blocked by SB742457 but not by the selective 5-hydroxytryptamine-2A (5HT2A) antagonist ketanserin) an
29 e on the postsynaptic serotonin-2A receptor (5-hydroxytryptamine-2A, or 5-HT2A) status were investiga
30 ion structure of a complex between the human 5-hydroxytryptamine 2B (5-HT2B) receptor and an antibody
31 assessed whether these polymorphisms affect 5-hydroxytryptamine 2B (5-HT2B) receptor in vitro pharma
32 ulatory function requires stimulation of the 5-hydroxytryptamine 2B receptor (5-HT(2B)) on HSCs by se
33 hat they and/or their metabolites are potent 5-hydroxytryptamine(2B) (5-HT(2B)) receptor agonists.
34 e intensity arising from fluorescence-tagged 5-hydroxytryptamine 2C (5-HT(2C)) receptors diffusing wi
35 express an eGFP-tagged form of the serotonin 5-hydroxytryptamine 2C (5-HT2C) receptor, global analysi
40 ethod is based on the serotonin 2C receptor (5-hydroxytryptamine(2C); 5HT(2C)) transcript, an RNA edi
42 other compared the relative efficacy of the 5-hydroxytryptamine-3 (5-HT(3)) receptor antagonists.
44 K1] receptor antagonist) and palonosetron (a 5-hydroxytryptamine-3 [5-HT3] receptor antagonist) for t
45 V management up to 72 h with the long-acting 5-hydroxytryptamine-3 receptor antagonist palonosetron.
48 tosensory cortex of the mouse, the serotonin 5-hydroxytryptamine 3A (5-HT(3A)) receptor, the only ion
49 ) has greater potency at mouse than at human 5-hydroxytryptamine 3A (5-HT3A) receptors, despite 84% a
50 domain 2 (TM2) to the TM2-TM3 loop, in mouse 5-hydroxytryptamine(3A) (5-HT(3A)) receptor function was
52 development of a PET radioligand for imaging 5-hydroxytryptamine (5-HT) 6 receptors in the brain woul
54 rrent activated by maximal concentrations of 5-hydroxytryptamine (5-HT) and increased the magnitude o
55 cted segments of native mouse intestine with 5-hydroxytryptamine (5-HT) and prostaglandin E2 (PGE2) i
57 ough there is general agreement that mucosal 5-hydroxytryptamine (5-HT) can initiate peristaltic refl
58 rn blot, whereas tryptophan, kynurenine, and 5-hydroxytryptamine (5-HT) concentrations were quantifie
61 transport protein which re-uptakes excessive 5-hydroxytryptamine (5-HT) from effective location to te
63 r (SERT) is responsible for the re-uptake of 5-hydroxytryptamine (5-HT) from the synaptic cleft after
65 lum) revealed significantly higher levels of 5-hydroxytryptamine (5-HT) in the striatum and hippocamp
66 ulation of cultured smooth muscle cells with 5-hydroxytryptamine (5-HT) induced PAK1 phosphorylation
72 ring reversal learning, whilst orbitofrontal 5-hydroxytryptamine (5-HT) likely mediates this type of
73 resent studies examined the acute effects of 5-hydroxytryptamine (5-HT) on NHE activity using Caco-2
79 read use of short-acting antagonists for the 5-hydroxytryptamine (5-HT) receptor, about 50% of patien
80 ty for beta-arrestin signaling at the 5-HT2B 5-hydroxytryptamine (5-HT) receptor, whereas they are re
81 entify that both ionotropic and metabotropic 5-hydroxytryptamine (5-HT) receptors are expressed on wh
82 duced inactivation and reactivation of human 5-hydroxytryptamine (5-HT) receptors in a recombinant ce
84 ntracellular free calcium ([Ca(2+)](i)), and 5-hydroxytryptamine (5-HT) release in human carcinoid BO
85 gene (Itgb3) on SERT function and selective 5-hydroxytryptamine (5-HT) reuptake inhibitor (SSRI) eff
86 rter inhibitor Prozac, the inhibition of the 5-hydroxytryptamine (5-HT) transporter by the ion channe
87 PKM Apl III in the sensory neuron 2 d after 5-hydroxytryptamine (5-HT) treatment reversed persistent
90 ted Sf9 cells, we show the inhibition of [3H]5-hydroxytryptamine (5-HT) uptake and [3H]dihydrotetrabe
91 , mucus release stimulated by either PGE2 or 5-hydroxytryptamine (5-HT) was approximately half that s
94 T function in vivo led to reduced serotonin (5-hydroxytryptamine (5-HT)) blood levels that paralleled
99 napse is dynamically regulated by serotonin (5-hydroxytryptamine (5-HT)) with elevated levels leading
100 d to elevated levels of embryonic serotonin (5-hydroxytryptamine (5-HT)), and we found that knockdown
105 ce Na(+) for driving transport and promoting 5-hydroxytryptamine (5-HT)-dependent conformational chan
106 in transporter (SERT) acting as a conduit to 5-hydroxytryptamine (5-HT)-mediated apoptosis, specifica
108 ggression in golden hamsters is inhibited by 5-hydroxytryptamine (5-HT)1A receptors and facilitated b
111 that acute stressors can increase serotonin [5-hydroxytryptamine (5-HT)] concentrations in the dorsom
112 body of literature has implicated serotonin [5-hydroxytryptamine (5-HT)] in descending modulation of
113 tle is known about the actions of serotonin [5-Hydroxytryptamine (5-HT)] in this region during develo
117 The dynamic interplay between serotonin [5-hydroxytryptamine (5-HT)] neurotransmission and the hy
119 ncoded Ile, Asn, and Ile (INI) of serotonin [5-hydroxytryptamine (5-HT)] receptor 2C (5-HT(2C)R) with
120 , we examined the hypothesis that serotonin [5-hydroxytryptamine (5-HT)] receptor activation enhances
121 vidence that cis-UCA binds to the serotonin [5-hydroxytryptamine (5-HT)] receptor with relatively hig
129 the foremost hypothesis of depression is the 5-hydroxytryptamine (5-HT, serotonin) deficiency hypothe
131 with a prenatal, genetically induced loss of 5-hydroxytryptamine (5-HT, serotonin) neurones are compr
134 e have found that the serotonin 1B receptor [5-hydroxytryptamine (5-HT1B) receptor] interacts with p1
135 is was reversed by systemic treatment with a 5-hydroxytryptamine (5-HT2C) receptor agonist and mimick
136 ression in the central nervous system (CNS), 5-hydroxytryptamine (5-HT: serotonin) subtype 6 receptor
137 is responsible for reuptake and recycling of 5-hydroxytryptamine (5-HT; serotonin) after its exocytot
139 ation studies suggest that variations in the 5-hydroxytryptamine (5-HT; serotonin) transporter (5-HTT
142 es were obtained for quipazine (nonselective 5-hydroxytryptamine [5-HT] agonist; 1.0-10.0 mg/kg), CGS
143 ays a critical role in regulating serotonin (5-hydroxytryptamine [5-HT]) availability in the gut.
145 We tested the hypothesis that serotonin (5-hydroxytryptamine [5-HT]) exerts stimulatory and inhib
147 s suggested an important role for serotonin (5-hydroxytryptamine [5-HT]) in enhancing the counterregu
153 different pruritogens, including serotonin (5-hydroxytryptamine [5-HT]), histamine, SLIGRL (protease
158 ed neurotrophic factor (BDNF) and serotonin (5-hydroxytryptamine, 5-HT) are known to regulate synapti
161 steroid (AAS) exposure and brain serotonin (5-hydroxytryptamine, 5-HT) depletion on behavior of pube
162 e as induced by an increase in serotonergic (5-hydroxytryptamine, 5-HT) efficacy has been a target of
163 associated with abnormalities in serotonin (5-hydroxytryptamine, 5-HT) in regions of the brainstem c
165 cleus (DR) is the major source of serotonin (5-hydroxytryptamine, 5-HT) in the forebrain and dysfunct
171 ong RVM neurons, we found that serotonergic (5-hydroxytryptamine, 5-HT) neurons decreased by 35% ipsi
173 paration to examine the effect of serotonin (5-hydroxytryptamine, 5-HT) receptor activation on segmen
174 aphe nuclei and expresses several serotonin (5-hydroxytryptamine, 5-HT) receptor subtypes, including
176 l trafficking of single groups of serotonin (5-hydroxytryptamine, 5-HT) receptors using single quantu
177 ine oxidase (MAOIs) and selective serotonin (5-hydroxytryptamine, 5-HT) reuptake (SSRIs) induces sero
178 r vesicular release, dopamine and serotonin (5-hydroxytryptamine, 5-HT) signaling is controlled by tr
184 osed mice had reduced contents of serotonin (5-hydroxytryptamine, 5-HT), a neurotransmitter involved
185 n-evoked reduction in hippocampal serotonin (5-hydroxytryptamine, 5-HT), as did the 5-HT(1A) receptor
186 tract contains much of the body's serotonin (5-hydroxytryptamine, 5-HT), but mechanisms controlling t
190 MAO A), the key enzyme catalyzing serotonin (5-hydroxytryptamine; 5-HT) and norepinephrine (NE) degra
192 use tyrosine hydroxylase (TH) and serotonin (5-hydroxytryptamine; 5-HT) immunoreactivity, in conjunct
194 raphe nucleus, which provides serotonergic (5-hydroxytryptamine; 5-HT) innervation to the nucleus ac
198 eory is that a breakdown in brain serotonin (5-hydroxytryptamine; 5-HT) signalling is critically invo
199 Presynaptic, plasma membrane serotonin (5-hydroxytryptamine; 5-HT) transporters (SERTs) clear 5-
203 the source of nearly all systemic serotonin (5-hydroxytryptamine; 5-HT), which is an important neurot
204 the source of nearly all systemic serotonin (5-hydroxytryptamine; 5-HT), which is an important neurot
210 s its role as a neurotransmitter, serotonin (5-hydroxytryptamine, 5HT) regulates inflammation and tis
213 thylamide (LSD) binding to recombinant human 5-hydroxytryptamine 6 (5-HT(6)) receptors expressed in C
214 onship (QSAR) models of compounds binding to 5-hydroxytryptamine-6 receptor (5-HT(6)R), a known targe
216 3-(piperazinylmethyl) indole derivatives as 5-hydroxytryptamine-6 receptor (5-HT6R) antagonists resu
217 ave previously reported on the unusual human 5-hydroxytryptamine(7) (h5-HT(7)) receptor-inactivating
218 scratching was observed following i.d. 5-HT (5-hydroxytryptamine), a protease-activated receptor (PAR
219 l that a distinct multiprotein complex links 5-hydroxytryptamine-activated intracellular signaling ev
220 T) is responsible for reuptake of serotonin (5-hydroxytryptamine) after its exocytotic release from n
221 meostasis, such as the melanocortin, leptin, 5-hydroxytryptamine and brain-derived neurotrophic facto
222 ated release of the peristaltic transmitters 5-hydroxytryptamine and calcitonin gene-related peptide;
223 f the pathway, the O-methylation of N-acetyl 5-hydroxytryptamine by hydroxyindole-O-methyltransferase
224 uced by acidic citrate, but not alpha-methyl-5-hydroxytryptamine, chloroquine, compound 48/80, or bil
225 l mucosal reflexes, which release serotonin (5-hydroxytryptamine) from enterochromaffin cells, and st
226 f single conformations of neutral serotonin (5-hydroxytryptamine) have been studied in the gas phase
228 ng a variety of cellular signals elicited by 5-hydroxytryptamine in both peripheral and central tissu
229 ellular signals elicited by serotonin (5-HT; 5-hydroxytryptamine) in both peripheral and central tiss
230 monoamine neurotransmitter serotonin (5-HT, 5-hydroxytryptamine) in the central nervous system, and
232 ke of the neurotransmitter, serotonin (5-HT; 5-hydroxytryptamine), into cells by the 5-HT transporter
233 he MAOA-L, by causing an ontogenic excess of 5-hydroxytryptamine, labilizes critical neural circuitry
236 , the mutant SNAP-25 could no longer support 5-hydroxytryptamine-mediated inhibition of exocytosis.
237 stigated the effect of diminished serotonin (5-hydroxytryptamine) neurotransmission using dietary try
238 significantly elevated levels of serotonin (5-hydroxytryptamine), norepinephrine, dopamine, and beta
240 electroactive chemical messenger serotonin (5-hydroxytryptamine or 5-HT) for the real-time measureme
243 mall molecules, we identified the serotonin (5-hydroxytryptamine or 5-HT) receptor antagonist metitep
245 aptic (type III) cells to release serotonin (5-hydroxytryptamine, or 5-HT) and norepinephrine (NE).
250 e not observed in response to acetylcholine, 5-hydroxytryptamine, or the protease-activated receptor-
251 ated and produced soluble factors serotonin (5-hydroxytryptamine), platelet factor 4, and platelet-ac
253 rmal unfolding of a homopentameric LGIC, the 5-hydroxytryptamine receptor (ligand binding, secondary
254 The objective of this study was to compare 5-hydroxytryptamine receptor 1A (5-HT(1A)) PET with cere
256 paper addresses whether the availability of 5-hydroxytryptamine receptor 1B (5-HT(1B)) is seen to de
257 , around 500 kb upstream of the locus HTR1E (5-hydroxytryptamine receptor 1E) locus, related to the s
258 e can result from the abrupt withdrawal of a 5-hydroxytryptamine receptor 2A antagonist from a treatm
259 appa-opioid receptors or blockade of 5-HT2A (5-hydroxytryptamine receptor 2A) receptors, suppressed m
261 tion studies linking the c.68C allele of the 5-hydroxytryptamine receptor 2C gene to lower seizure ri
265 e, and administration of dexamethasone and a 5-hydroxytryptamine receptor antagonist such as ondanset
267 of the G alpha(q)-linked serotonin receptor 5-hydroxytryptamine receptor-2b (Htr2b) in maternal isle
270 istic receptors of enteric neurons, Ret, and 5-hydroxytryptamine-receptor subtypes at 33 degrees C an
271 ide Y, vasoactive intestinal peptide, or the 5-hydroxytryptamine (serotonin) 3a receptor, were silent
273 is a selective, high-affinity agonist of the 5-hydroxytryptamine (serotonin) receptor 4 that enhances
274 rescent photoproducts of the hydroxyindoles, 5-hydroxytryptamine (serotonin), 5-hydroxytrptophan, and
275 )/Cl(-)-dependent transporters for dopamine, 5-hydroxytryptamine (serotonin), noradrenaline, GABA and
276 litation (LTF) of sensory neuron synapses by 5-hydroxytryptamine (serotonin; 5-HT) requires the activ
277 ety of new antiemetic medications, primarily 5-hydroxytryptamine subtype 3 receptor antagonists, as w
281 ect an influence of natural variation in the 5-hydroxytryptamine transporter (5-HTT) gene on multiple
282 the gene encoding the serotonin transporter [5-hydroxytryptamine transporter (5-HTT)] affect the tran
283 ned treatment of C6 glioma cells, which lack 5-hydroxytryptamine transporters, showed marked concentr
284 by spinal delivery of duloxetine acting via 5-hydroxytryptamine type 2A receptors and temporally coi
285 transmembrane domain (M3) is conserved among 5-hydroxytryptamine type 3 (5-HT(3)) receptor subunits a
290 this article, we discuss the pharmacology of 5-hydroxytryptamine type 3 receptor antagonists and the
291 atients may help differentiate responders to 5-hydroxytryptamine type 3 receptor antagonists from non
294 te-binding cassette subfamily B member 1 and 5-hydroxytryptamine type 3 receptor subunits also contri
295 ily of pentameric ligand-gated ion channels, 5-hydroxytryptamine type 3 receptors (5-HT3Rs) are activ
296 ethasone, aprepitant or fosaprepitant, and a 5-hydroxytryptamine type 3-receptor antagonist, in patie
297 rg(436) and Arg(440)) within the MA helix of 5-hydroxytryptamine type 3A (5-HT3A) receptors act singu
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。